---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-019161"
form_type: "8-K"
ticker: "RLYB"
cik: "0001739410"
company_name: "Rallybio Corp"
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:35:38.621919+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rallybio Q1 net loss $17.3M; cash $150.4M; RLYB212 data expected Q4 2023

## Summary
- Net loss $17.3M ($0.43 per share) vs $14.5M ($0.48) in Q1 2022.
- Cash, cash equivalents and marketable securities $150.4M as of March 31, 2023; runway into Q1 2025.
- RLYB212 multiple dose cohort initiated; Phase 1b data to be presented at ISTH June 2023; cohort data expected Q4 2023.
- RLYB116 multiple ascending dose study ongoing; initial safety, PK and PD data expected Q4 2023.
- Research collaboration with EyePoint announced for sustained intraocular delivery of C5 inhibitor targeting geographic atrophy.

## SEC filing metadata
- accession: 0000950170-23-019161
- form_type: 8-K
- ticker: RLYB
- cik: 0001739410
- company_name: Rallybio Corp
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739410/000095017023019161/0000950170-23-019161-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739410/000095017023019161/rlyb-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-019161
- JSON: https://secwatch.observer/filing/0000950170-23-019161.json
- Plain text: https://secwatch.observer/filing/0000950170-23-019161.txt

## Key facts
- Earnings Releases
  Rallybio Corp reported first quarter ended March 31, 2023 results: net income $17.3 million, EPS $0.43.
  - Period: first quarter ended March 31, 2023
  - Net income: $17.3 million
  - EPS: $0.43
  - Result: reported results
  source text: Net loss was $17.3 million for the first quarter of 2023, or net loss per common share of $0.43 compared to a net loss of $14.5 million, or net loss per common share of $0.48 for the first quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739410/000095017023019161/0000950170-23-019161-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.